Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Leuk Res. 2010 Mar 23;34(8):969–973. doi: 10.1016/j.leukres.2010.02.033

Table 1.

Clinical and pathologic features of patients with RARS-T.

Patient No. Age Plt. Count, (× 109/L) Fibrosis WBC (× 10∧9/L) Splenomegaly TET2 ASXL1 JAK2 V617F MPL W515L pSTAT5 Cytogenetics SNP-A karyotyping
Gain Loss UPD
1*†‡ 78 277§ 2+ 19.5 N - - - + + 46,XY[20] - - -
2*† 73 664 2+ 10.14 Y delC 1480Sfs NA - - + 46,XY[20] - - -
3 79 660 4+ 23.84 Y - - + + + 46,XX,inv(9)(p11;q12)[20] - 2p16.2; 22q11.23 1p11.2p-ter
4 76 587 1+ 28.06 Y - - + - + 46,XY[20] - - 9p13.1-pter
5 71 766 4+ 26.2 Y - L1395V - - + 46,XY[20] - - -
6 57 600 4+ 37.09 Y - - + - + 46,XX[20] - # - # - #
7 78 894 2+ 3.81 N - - + - + 46,XX[20] - - -
8 58 771 0 9.99 N - - - - + 46,XX[20] - - -
9 87 625 2+ 15.4 Y - - - + + 46,XY[20] - - 1p13.3-pter 2p12-pter 6p21.2-p22.1 6p16.3-q22.33 8p21.3-q24.13 10p13-p14
10 78 483 NA 22.48 N - - - - + 46, XY,inv(3)(q21;q26.2)[20] 11p25 - -
11*†‡ 61 329π 2+ 90.34 Y - - + - + 46,XY[20] - - -
12*† 85 598 1+/2+ 21.8 N - NA + - + 46,XX[20] 7q21.2 - -
13 71 496 0 4.14 N - NA + - NA 5q- 20q13.12 - 1p32-pter
14*† 72 512 0 8.1 N - - + - NA 45,X,inv(10)(q21.2;q24.3)[3]
46,XX,inv(10)(q21.2;q24.3)[17]
- - -
15 66 773 NA 5.39 N - - - - - 45,X,-X[4]/46,XX[16] 2p11.23 Xq25 -
16 69 616 2+ 4.26 Y NA - - - - 46,XY,del(5)(q22;q33)[20] - 5q21.1q31.3 1p35.1-pter
17 63 611 0 4.99 N - - - - - 46,XX[20] 21q22.3 - -
18†‡ 73 667 2+ 33.46 N V1718L - - - - 47,XX,+8[20] 8 - -
19 83 469 NA 4.6 N - Q1102D - - NA 46,XX[20] NA NA NA
20 63 614 NA 14.36 Y - - - - - 46,XX[20] - - 2p22.3-pter 3q21.3qter
21 61 457 0 5.79 N - - - - - 46,XX,add(15)(p11.1),add(22)(p11.2)[3]/47,idem, +19 [19] +19 - -
22 83 636 1+ 5.30 N - - - - - 46,XY[20] - - -
23 80 761 0 8.27 N - - - - NA 46,XX[20] - - 3q21.3qter
*,†,‡

Patients were part of a previous series where mutation analysis was confined to JAK2 V617F/MPL W515L mutations and pSTAT5 analysis [1,11,15]; NA - not available;

§

documented history of thrombocytosis over previous 6 months (to 1353×109/l);

π

documented history of thrombocytosis over previous 6 months (546–1213×109/l);

#

used 50K array.